Topic: mGluR2

Amphetamine is used in the therapy of mental disorders and for recreational purposes. However, repeated exposures lead to amphetamine sensitization (AS), which is associated with hyperdopaminergia, cognitive dysfunctions, and aberrant behavior. Notably, mounting evidence indicates that activation of group II metabotropic glutamate receptors (mGluR2 and mGluR3) reverses neuroplasticity associated with AS and prevents both, anxiety and psychosis, in rodent models.We employed a system-oriented approach, murine model of AS, and selective pharmacological tools to explore the specific contribution o

Immunotherapy of Alzheimer’s disease (AD) is a promising approach to reduce the accumulation of amyloid-beta (Aβ) peptides, a critical event in the onset of the disease. Emerging evidence indicate that metabotropic glutamate receptors (mGluRs) are involved in the progression of AD, representing potential targets for new treatments. Studies have highlighted the potential role of group II mGluRs, mGluR2 and mGluR3, in the modulation of Aβ production, although their respective contribution remains unclear, due to the lack of specific tools to study them. Here, we showed in vitro that enhancing mG

Current therapies for Alcohol Use Disorder (AUD) exhibit significant variability in effectiveness, resulting in high relapse rates. Addressing this challenge requires a precision medicine approach incorporating biomarkers responsive to novel treatments. A promising approach involves bioelectronic devices utilising neuroelectric signatures of impaired prefrontal function, a key feature in AUD resulting in diminished inhibitory control over compulsive behaviour and increased vulnerability to relapse. Thus, we reason that event-related potentials and neural oscillations are valuable biomarkers fo